Rational Pharmacotherapy in Cardiology

Advanced search

Association of polymorphic variants of CYP2C19, P2RY12, ITGB3, ITGA2 and eNOS3 genes with high residual platelet reactivity while taking clopidogrel and acetylsalicylic acid at different terms of myocardial infarction


Aim. Study of the association of polymorphic variants of CYP2C19 (G681A), P2RY12 (H1/H2), ITGB3 (T1565C), ITGA2 (C807T), eNOS3 (T786C) genes with high residual platelet reactivity (HRPR) to clopidogrel and acetylsalicylic acid (ASA) at different terms of myocardial infarction (MI).

Material and methods. The study included 400 patients with MI aged 31-74 years, 317 (79,3%) men and 83 (20,7%) women. Platelet aggregation performed on days 1-2, 12-14 and 28-30 of MI, and genotyping by the polymerase chain reaction were analyzed using the STATISTICA 10.0 program.

Results. Differences were found in ADP-test 1-3 depending on the CYP2C19 (G681A) polymorphism, ADP-test 1 depending on the P2RY12 (H1/H2) polymorphism, ADP-test 2 depending on the ITGB3 (T1565C) polymorphism, ASPI-test 1 depending on the eNOS (T786C) polymorphism. The risk of HRPR to clopidogrel is higher in 681A CYP2C19 allele carriers compared to the G681 carriers throughout the entire observation period: initially odds ratio (OR) of 1,8 (1,14-2,88), p=0,012, on days 12-14 of MI, OR of 1,7 (1,08-2,68), p=0,023 and on days 28-30 of MI, OR of 2,3 (1,42-3,81), p=0,0008. The risk of HRPR to clopidogrel is higher in AA CYP2C19 genotype carriers compared to GG genotype carriers, on days 1-2 of MI (OR 6,5 (1,16-36,4), p=0,033), on days 28-30 of MI (OR 7,8 (1,26-48,0), p=0,027). The risk of HRPR to clopidogrel on days 1-2 of MI is higher in H2 P2RY12 locus carriers compared to H1 locus carriers (OR 1,5 (1,02-2,22), p=0,039). The risk of HRPR to ASA on days 1-2 of MI is higher in the 786C eNOS3 allele carriers compared to T786 allele carriers (OR 1,4 (1,02-1,96), p=0,036). Carriers of haplotypes of minor alleles of CYP2C19 + ITGA2 + P2RY12 + eNOS genes (OR 3,9 (1,13-13,65), p=0,032) and CYP2C19 + ITGA2 + eNOS genes (OR 5,1 (1,7214,96), p=0,0032) have higher risk of HRPR to dual antiplatelet therapy (DAPT) on days 28-30 of MI compared to the rest of patients.

Conclusion. The association of HRPR to clopidogrel with the CYP2C19 (G681A) polymorphism was found during the entire observation period, with the P2RY12 (H1/H2) polymorphism on days 1-2 of MI, with the ITGB3 (T1565C) polymorphism on days 10-12 of MI. The association of HRPR to ASA with eNOS (T786C) polymorphism was found on days 1-2 of MI. Minor allele haplotypes of the CYP2C19 + ITGA2 + P2RY12 + eNOS genes and CYP2C19 + ITGA2 + eNOS genes were associated with a higher risk of developing HRPR to DAPT on days 28-30 of MI.

About the Authors

T. P. Pronko
Grodno State Medical University

Tatyana P. Pronko

V. A. Snezhitskiy
Grodno State Medical University

Viktor A. Snezhitskiy

T. L. Stepuro
Grodno State Medical University

Tatsiana L. Stepuro

A. V. Kapytski
Grodno State Medical University

Andrei V. Kapytski


1. Kropacheva ES. Pharmacogenetics of antithrombotic drugs: status update on the problem. Atherothrombosis. 2018;(2):115-29 (In Russ.) DOI:10.21518/2307-11092018-2-115-129.

2. Strisciuglio T, Franco D, Di Gioia G, et al. Impact of genetic polymorphisms on platelet function and response to anti platelet drugs. Cardiovasc Diagn Ther. 2018;8(5):610-20. DOI:10.21037/cdt.2018.05.06.

3. Fatini C, Sticchi E, Bolli P, et al. eNOS gene influences platelet phenotype in acute coronary syndrome patients on dual antiplatelet treatment. Platelets. 2009;20(8):548-54. DOI:10.3109/09537100903337401.

4. Calatzis A, Spannagl M, Loreth R. Multiplate® platelet function analysis — application and interpretation. V2.0/07.2007. Monachium, Germany: Dynabyte Medical; 2007.

5. Jarrar M, Behl S, Manyam G, et al. Cytochrome allelic variants and clopidogrel metabolism in cardiovascular diseases therapy. Mol Biol Rep. 2016;43(6):473-84. DOI:10.1007/s11033-016-3983-1.

6. Huang S, Yang S, Ly S, et al. Clinical non-effectiveness of clopidogrel use for peripheral artery disease in patients with CYP2C19 polymorphisms: a systematic review. Eur J Clin Pharmacol. 2022;78(8):1217-25. DOI:10.1007/s00228-02203346-7.

7. Pare G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med. 2010;363(18):1704-14. DOI:10.1056/NEJMoa1008410.

8. Chang R, Zhou W, Ye Y, et al. Relationship between CYP2C19 polymorphism and clopidogrel resistance in patients with coronary heart disease and ischemic stroke in China. Genet Res (Camb). 2022;2022:1901256. DOI:10.1155/2022/1901256.

9. Chernov AA, Mirzaev KB, Sychev DA. The first meta-analysis of domestic pharmacogenetic studies of clopidogrel. Pharmacogenetics and Pharmacogenomics. 2015;(2):19-23 (In Russ.)

10. Kantemirova BI, Orlova EA, Polunina OS, et al. Pharmacogenetic bases of individual sensitivity and personalized administration of antiplatelet therapy in different ethnic groups. Pharmacy & Pharmacology. 2020;8(6):392-404 (In Russ.) DOI:10.19163/2307-92662020-8-6-392-404.

11. AlMukdad S, Elewa H, Al-Badriyeh D. Economic evaluations of CYP2C19 genotype-guided antiplatelet therapy compared to the universal use of antiplatelets in patients with acute coronary syndrome: a systematic review. J Cardiovasc Pharmacol Ther. 2020;25(3):201-11. DOI:10.1177/1074248420902298.

12. Nie XY, Li JL, Zhang Y, et al. Haplotype of platelet receptor P2RY12 gene is associated with residual clopidogrel on-treatment platelet reactivity. J Zhejiang Univ Sci B. 2017;18(1):37-47. DOI:10.1631/jzus.B1600333.

13. Idrissi HH, Hmimech W, Khorb NEl, et al. Does i-T744C P2Y12 polymorphism modulate clopidogrel response among moroccan acute coronary syndromes patients? Genet Res Int. 2017;2017:9532471. DOI:10.1155/2017/9532471.

14. Cui G, Zhang S, Zou J, et al. P2Y12 receptor gene polymorphism and the risk of resistance to clopidogrel: a meta-analysis and review of the literature. Adv Clin Exp Med. 2017;26(2):343-49. DOI:10.17219/acem/63745.

15. Tang XF, Zhang JH, Wang J, et al. Effects of coexisting polymorphisms of CYP2C19 and P2Y12 on clopidogrel responsiveness and clinical outcome in patients with acute coronary syndromes undergoing stent-based coronary intervention. Chin Med J (Engl). 2013;126(6):1069-75.

16. Danielak D, Pawlak K, Główka F, et al. Influence of genetic and epigenetic factors of P2Y12 receptor on the safety and efficacy of antiplatelet drugs. Cardiovasc Drugs Ther. 2022. DOI:10.1007/s10557-022-07370-8. Online ahead of print.

17. Oestreich JH, Steinhubl SR, Ferraris SP, et al. Effect of genetic variation in P2Y12 on TRAP-stimulated platelet response in healthy subjects. J Thromb Thrombolysis. 2014;38(3):372-79. DOI:10.1007/s11239-014-1058-5.

18. Ge H, Zhou Y, Liu X, et al. Relationship between plasma inflammatory markers and platelet aggregation in patients with clopidogrel resistance after angioplasty. Angiology. 2012;63(1):62-6. DOI:10.1177/0003319711406432.

19. Gasperi V, Catani MV, Savini I. Platelet responses in cardiovascular disease: sexrelated differences in nutritional and pharmacological interventions. Cardiovasc Ther. 2020;2020:2342837. DOI:10.1155/2020/2342837.

20. Cavallari U, Trabetti E, Malerba G, et al. Gene sequence variations of the platelet P2Y12 receptor are associated with coronary artery disease. BMC Med Genet. 2007;8(59):1-6. DOI:10.1186/1471-2350-8-5.

21. Floyd CN, Ferro A, Warner TD. Expression of the PlA2 allele of glycoprotein IIIa and its impact on platelet function. JRSM Cardiovasc Dis. 2015;4: 2048004015610252. DOI:10.1177/2048004015610252.

22. Semashchenko KS, Mongush TS, Kosinova AA, et al. Study the association of nucleotide polymorphisms in platelet receptor and cytochrome P450 genes with the development of resistance to antiplatelet drugs in patients with coronary artery disease. Rational Pharmacotherapy in Cardiology. 2022;18(3):289-96 (In Russ.) DOI:10.20996/18196446-2022-06-15.

23. Strambovskaya NN. Platelet functions in healthy persons with genetic polymorphisms GPIA(С807Т), GPIIIA(Т1565С), GPIβα(С434Т), P2RY12(Н1/Н2), SELP(G1087A) platelet receptions. Acta Biomedica Scientifica. 2013;94(6):6570 (In Russ.)

24. Grinshtein YuI, Kosinova AA, Grinshtein IY, et al. Possible Genetic Predictors of Cardiovascular Events After Coronary Bypass Surgery. Kardiologiia. 2018;58(7):77-84 (In Russ.) DOI:10.18087/cardio.2018.7.10148.

25. Karazhanova LK, Zhukusheva ShT, Еsimbekova EI, et al. The prevalence of poly morphisms of some genes associated with the function of plasmaplatelet hemostasis, with aspirin resistance in the kazakh population. Science & Healthcare 2018;20(5):164-71 (In Russ.)

26. Jastrzebska M, Lisman D, Szelepajlo A, et al. Evaluation of platelet reactivity during combined antiplatelet therapy in patients with stable coronary artery disease in relation to diabetes type 2 and the GPIIB/IIIA receptor gene polymorphism. J Physiol Pharmacol. 2019;70(2):175-85. DOI:10.26402/jpp.2019.2.01.

27. Arya V, Mahajan P, Saraf A, et al. Association of CYP2C19, CYP3A5 and GPIIb/ IIIa gene polymorphisms with aspirin and clopidogrel resistance in a cohort of Indian patients with coronary artery disease. Int J Lab Hematol. 2015;37(6):80918. DOI:10.1111/ijlh.12416.

28. Floyd CN, Ferro A. The PlA1/A2 polymorphism of glycoprotein IIIa in relation to efficacy of antiplatelet drugs: a systematic review and meta-analysis. Br J Clin Pharmacol. 2014;77(3):446-57. DOI:10.1111/bcp.12204.

29. Muslimova EF, Afanasiev SA, Rebrova TYu, et al. Association of ITGB3, P2RY12, and CYP2C19 gene polymorphisms with platelet functional activity in patients with coronary heart disease during dual antiplatelet therapy. Ter Arkhiv. 2017;89(5):74-8 (In Russ.) DOI:10.17116/terarkh201789574-78.

30. Weng Z, Li X, Li Y, et al. The Association of four common polymorphisms from four candidate genes (COX-1, COX-2, ITGA2B, ITGA2) with aspirin insensitivity: a metaanalysis. PLoS ONE. 2013;8(11):e78093. DOI:10.1371/journal.pone.0078093.

31. Wang H, Sun X, Dong W, et al. Association of GPIa and COX-2 gene polymorphism with aspirin resistance. J Clin Lab Anal. 2018;32(4):e22331. DOI.10.1002/jcla.22331.

32. Al-Azzam SI, Alzoubi KH, Khabour OF, et al. The contribution of platelet glycoproteins (GPIa C807T and GPIba C-5T) and cyclooxygenase 2 (COX-2G765C) polymorphisms to platelet response in patients treated with aspirin. Gene. 2013;526(2):118-21. DOI:10.1016/j.gene.2013.04.083.

33. Mukarram O, Akhtar N, Junaid A, et al. A study into the genetic basis of aspirin resistance in Pakistani patients with coronary artery disease. Pak J Pharm Sci. 2016;29(4):1177-82.

34. Shishkina EA, Khlynova OV, Vasilets LM, et al. Role of C807T polymorphism of ITGA2 gene of collagen receptor and platelet aggregation activity in patients with arterial hypertension. Kazan Medical Journal. 2019;100(3):386-91 (In Russ.) DOI:10.17816/KMJ2019-386.

35. Muslimova EF, Rebrova TYu, Afanasiev SA, et al. Genotype -786CC of the endothelial nitric oxide synthase gene NOS3 as a factor of adverse coronary heart disease course and increased on-treatment platelet aggregation. Russian Journal of Cardiology. 2017;(10):29-32 (In Russ.) DOI:10.15829/1560-4071-2017-10-29-32.

Supplementary files


For citations:

Pronko T.P., Snezhitskiy V.A., Stepuro T.L., Kapytski A.V. Association of polymorphic variants of CYP2C19, P2RY12, ITGB3, ITGA2 and eNOS3 genes with high residual platelet reactivity while taking clopidogrel and acetylsalicylic acid at different terms of myocardial infarction. Rational Pharmacotherapy in Cardiology. 2023;19(3):222-229. (In Russ.)

Views: 662

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)